October 2, 2017 09:16 AM EDT
News Briefing

Rigel surges as FDA waives pan­el; Trou­bled En­do­cyte looks for come­back fol­low­ing $12M li­cens­ing deal; Seat­tle Ge­net­ics scores a ‘break­through’

Shehla Shakoor

Managing Director

→ Shares of Rigel Ther­a­peu­tics $RIGL bound­ed up about 20% this morn­ing af­ter the biotech re­port­ed that the FDA has no plans to call …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Oma­da Health rose 21% in its pub­lic mar­ket de­but

Re­cur­sion to lay off 20% of staff, a month af­ter slash­ing its pipeline

Odyssey pulls back from IPO plans as pub­lic mar­kets re­main frozen

Ex­clu­sive: Re­boot­ing dead hu­man brains, a biotech start­up seeks to rein­vent ear­ly drug test­ing work

Up­dat­ed: Mer­ck wins FDA ap­proval for RSV an­ti­body drug, mak­ing a hot mar­ket more com­pet­i­tive

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times